Immorta Bio Completes Preclinical Trials for AI-Designed Peptide Targeting Senescent Cells

Key points

• SenoMune-0257 is a synthetic peptide identified using artificial intelligence to stimulate cytotoxic T cells against senescent cells.
• The molecule aims to address chronic inflammation and tissue deterioration associated with aging diseases like cancer and neurodegeneration.
• Immorta Bio states the peptide offers durable immunological memory and lower manufacturing costs compared to personalized cell therapies.
• Preclinical studies showed the peptide could selectively clear senescent cells while sparing healthy ones in laboratory conditions.
• The company expects to initiate human trials before the end of 2026, though specific trial details remain undisclosed.

Background

This development follows earlier work on SenoVax, a cellular immunotherapy that showed promise in extending survival in experimental models. Immorta Bio’s new peptide approach simplifies this by creating an off-the-shelf product rather than a personalized therapy. The company has previously collaborated with institutions like the Buck Institute and Cedars-Sinai on aging-related research.

Why it matters

If successful, SenoMune-0257 could provide a scalable and affordable method for clearing senescent cells, which are linked to numerous age-related diseases. This could significantly reduce the cost and complexity of senolytic treatments, making them more accessible for widespread use.

What to watch

Immorta Bio plans to begin human evaluations of SenoMune-0257 before the end of 2026. The company has not yet disclosed details regarding regulatory applications, trial locations, or participant numbers.